Stavudine- and nevirapine-related drug toxicity while on generic fixed-dose antiretroviral treatment: incidence, timing and risk factors in a three-year cohort in Kigali, Rwanda

Transactions of the Royal Society of Tropical Medicine and Hygiene

Volumn 104, Issue 2, 2010, Pages 148-153

  van Griensven, Johan ^a   Zachariah, Rony ^a   Rasschaert, Freya ^a   Mugabo, Jules ^b   Atté, Edi F ^a   Reid, Tony ^a  

^a MÉDECINS SANS FRONTIÈRES   (Belgium)

^b TRAC Plus Center for Treatment and Research on AIDS   (Rwanda)

Author keywords

Africa; Antiretroviral; HIV; Nevirapine; Stavudine; Toxicity

Indexed keywords

LAMIVUDINE; LAMIVUDINE PLUS NEVIRAPINE PLUS STAVUDINE; NEVIRAPINE; STAVUDINE;

ADULT; AGE; ARTICLE; BODY WEIGHT; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLACTATEMIA; LACTIC ACIDOSIS; LIPOATROPHY; LIVER FUNCTION TEST; LIVER TOXICITY; LOWEST INCOME GROUP; MAJOR CLINICAL STUDY; MALE; NEUROPATHY; PATIENT COMPLIANCE; PATIENT MONITORING; PERIPHERAL NEUROPATHY; RASH; RISK FACTOR; RWANDA; SEX DIFFERENCE; SKIN TOXICITY; TIME; UNSPECIFIED SIDE EFFECT;

ACIDOSIS, LACTIC; ADULT; AGE FACTORS; ANTI-HIV AGENTS; DRUG THERAPY, COMBINATION; DRUGS, GENERIC; EXANTHEMA; FEMALE; HIV INFECTIONS; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HUMANS; LONGITUDINAL STUDIES; MALE; NEVIRAPINE; PERIPHERAL NERVOUS SYSTEM DISEASES; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; RWANDA; STAVUDINE; TIME FACTORS;

EID: 75449111630     PISSN: 00359203     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.trstmh.2009.07.009     Document Type: Article

References (19)

1. WHO. Towards universal access: scaling up priority HIV/AIDS interventions in the health sector: progress report, June 2008. Geneva: World Health Organization; 2008.
2. Makinson A., Moing V.L., Kouanfack C., Laurent C., and Delaporte E. Safety of stavudine in the treatment of HIV infection with a special focus on resource-limited settings. Expert Opin Drug Saf 7 (2008) 283-293
3. WHO. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach. Geneva: World Health Organization; 2006.
4. Hill A., Ruxrungtham K., Hanvanich M., Katlama C., Wolf E., Soriano V., et al. Systematic review of clinical trials evaluating low doses of stavudine as part of antiretroviral treatment. Expert Opin Pharmacother 8 (2007) 679-688
5. WHO. Report on WHO/UNAIDS meeting on forecasting ARV needs up to 2010; 7-8 November 2005. Geneva: World Health Organization; 2006.
6. Rivero A., Mira J.A., and Pineda J.A. Liver toxicity induced by non-nucleoside reverse transcriptase inhibitors. J Antimicrob Chemother 59 (2007) 342-346
7. Subbaraman R., Chaguturu S.K., Mayer K.H., Flanigan T.P., and Kumarasamy N. Adverse effects of highly active antiretroviral therapy in developing countries. Clin Infect Dis 45 (2007) 1093-1101
8. Murphy R.A., Sunpath H., Kuritzkes D.R., Venter F., and Gandhi R.T. Antiretroviral therapy-associated toxicities in the resource-poor world: the challenge of a limited formulary. J Infect Dis 196 Suppl 3 (2007) S449-S456
9. Calmy A., Ford N., Hirschel B., Reynolds S.J., Lynen L., Goemaere E., et al. HIV viral load monitoring in resource-limited regions: optional or necessary?. Clin Infect Dis 44 (2007) 128-134
10. Carr A., and Law M. An objective lipodystrophy severity grading scale derived from the lipodystrophy case definition score. J Acquir Immune Defic Syndr 33 (2003) 571-576
11. van Griensven J., De Naeyer L., Mushi T., Ubarijoro S., Gashumba D., Gazille C., et al. High prevalence of lipoatrophy among patients on stavudine-containing first-line antiretroviral therapy regimens in Rwanda. Trans R Soc Trop Med Hyg 101 (2007) 793-798
12. Lichtenstein K.A., Ward D.J., Moorman A.C., Delaney K.M., Young B., Palella Jr. F.J., et al. Clinical assessment of HIV-associated lipodystrophy in an ambulatory population. AIDS 15 (2001) 1389-1398
13. van Griensven J., Zachariah R., Rasschaert F., Atte E.F., and Reid T. Weight evolution in HIV-1 infected women in Rwanda after stavudine substitution due to lipoatrophy: comparison of zidovudine with tenofovir/abacavir. Trans R Soc Trop Med Hyg 103 (2009) 613-619
14. van Griensven J, Corthouts A, Atté EF, Alonso J. Symptomatic lactic acidaemia on stavudine-containing ART: clinical features of 20 cases and risk factor assessment [abstract 1090]. Program and abstracts of the 2007 HIV/AIDS Implementers' Meeting; 16-19 June 2007; Kigali, Rwanda.
15. van Griensven J., Atte E.F., and Reid T. Symptomatic hyperlactatemia: lessons learned using a point-of-care device in a health care center- and nurse-based antiretroviral program in Rwanda. Clin Infect Dis 46 (2008) 320-322
16. Bolhaar M.G., and Karstaedt A.S. A high incidence of lactic acidosis and symptomatic hyperlactatemia in women receiving highly active antiretroviral therapy in Soweto, South Africa. Clin Infect Dis 45 (2007) 254-260
17. Boulle A., Orrel C., Kaplan R., Van Cutsem G., McNally M., Hilderbrand K., et al. Substitutions due to antiretroviral toxicity or contraindication in the first 3 years of antiretroviral therapy in a large South African cohort. Antivir Ther 12 (2007) 753-760
18. Hoffmann C.J., Charalambous S., Thio C.L., Martin D.J., Pemba L., Fielding K.L., et al. Hepatotoxicity in an African antiretroviral therapy cohort: the effect of tuberculosis and hepatitis B. AIDS 21 (2007) 1301-1308
19. Sanne I., Mommeja-Marin H., Hinkle J., Bartlett J.A., Lederman M.M., Maartens G., et al. Severe hepatotoxicity associated with nevirapine use in HIV-infected subjects. J Infect Dis 191 (2005) 825-829